Browse > Article

Anticancer Effect of Activated Natural Killer Cells on Human Non-small Cell Lung Cancer  

Park, Min-Gyeong (Division of Pharmacological Research, KFDA)
Sung, Hye-Ran (Department of Comprehensive Melanoma Research Center (CMRC), H. Lee Moffitt Cancer Center & Research Institute)
Park, Ji-Sung (College of Pharmacy, Chungbuk National University)
Kim, Jee-Youn (College of Pharmacy, Chungbuk National University)
Han, Sang-Bae (College of Pharmacy, Chungbuk National University)
Lee, Chong-Kil (College of Pharmacy, Chungbuk National University)
Yun, Byung-Kui (NKBIO Ltd.)
Song, Suk-Gil (College of Pharmacy, Chungbuk National University)
Publication Information
YAKHAK HOEJI / v.55, no.3, 2011 , pp. 267-272 More about this Journal
Abstract
Human NK cells, identified 30 years ago based on their ability to spontaneously kill tumor cells, constitute a subset of lymphocytes, which play an important role in the first line of immune defense and the effective function of these cells are enhanced by cytokines. Lung carcinoma has been one of the most commonly diagonosed cancer as well as the leading cause of cancer death in male. Here we provide the evidence that human natural killer cells has inhibitory effects on tumor growth of human lung cancer cell NCI-H460 (non-small cell lung cancer). Enriched NK cell population was obtained by 2 weeks cultivation in interleukin-2(IL-2)-containing medium. The resulting population comprised 26% CD3$^+$ cells, 9% CD3$^+$CD4$^+$ cells, 16% CD3$^+$CD8$^+$ cells, 76% CD56$^+$ cells, 6% CD3$^+$CD56$^+$ cells and 70% CD3$^-$CD56$^+$ cells. Activated NK cells at doese of 2.5, 5, and 10 million cells per mouse inhibited 2%, 12% and 45% of NCI-H460-induced tumor growth in nude mouse xenograft assays, repectively. This result suggests that NK cell-based immunotherapy may be used as an adoptive immunotherapy for lung cancer patients.
Keywords
natural killer cells; immunotherapy; NCI-H460 lung cancer;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Kakimi, K., Nakajima, J. and Wada, H. : Active specific immunotherapy and cell-transfer therapy for treatment of nonsmall cell lung cancer. Lung. Cancer. 65, 1 (2009).   DOI   ScienceOn
2 Kim, H. M., Kang, J. S., Lim, J., Park, S. K., Lee, K., Yoon, Y. D., Lee, C. W., Lee, K. H., Han, G., Yang, K. H., Kim, Y. J., Kim, Y. and Han, S. B. : Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch. Pharm. Res. 30, 1464 (2007).   DOI
3 Imai, K., Matsuyama, S., Miyake, S., Suga, K. and Nakachi, K. : Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 356, 1795 (2000).   DOI   ScienceOn
4 Whiteside, T. L. and Herberman, R. B. : Role of human natural killer cells in health and disease. Clin. Diagn. Lab. Immunol. 1, 125 (1994).
5 Escudier, B., Farace, F., Angevin, E., Charpentier, F., Nitenberg, G., Triebel, F. and Hercend, T. : Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2. Eur. J. Cancer. 30A, 1078 (1994).
6 Carlens, S., Gilljam, M., Chambers, B. J., Aschan, J., Guven, H., Ljunggren, H. G., Christensson, B. and Dilber, M. S. : A new method for in vitro expansion of cytotoxic human CD3- CD56+ natural killer cells. Hum. Immunol. 62, 1092 (2001).   DOI   ScienceOn
7 Klingemann, H. G. : Natural killer cell-based immunotherapeutic strategies. Cytotherapy 7, 16 (2005).   DOI
8 Alici, E., Sutlu, T., Björkstrand, B., Gilljam, M., Stellan, B., Nahi, H., Quezada, H. C., Gahrton, G., Ljunggren, H. G. and Dilber, M. S. : Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 111, 3155 (2008).   DOI   ScienceOn
9 Guven, H., Gilljam, M., Chambers, B. J., Ljunggren, H. G., Christensson, B., Kimby, E. and Dilber, M. S. : Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia. 17, 1973 (2003).   DOI   ScienceOn
10 Thorne, S. H., Negrin, R. S. and Contag, C. H. : Synergistic antitumor effects of immune cell-viral biotherapy. Science 311, 1780 (2006).   DOI
11 Whiteside, T. L. and Herberman, R. B. : The role of natural killer cells in immune surveillance of cancer. Curr. Opin. Immunol. 7, 704 (1995).   DOI   ScienceOn
12 Bobek, V., Boubelik, M., Fiserova, A., L'uptovcova, M., Vannucci, L., Kacprzak, G., Kolodzej, J., Majewski, A. M. and Hoffman, R. M. : Anticoagulant drugs increase natural killer cell activity in lung cancer. Lung Cancer. 47, 215 (2005).   DOI   ScienceOn
13 Voskoglou-Nomikos, T., Pater, J. L. and Seymour, L. : Clinical predictive value of the invitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Can. Res. 9, 4227 (2003).
14 Albertsson, P. A., Basse, P. H., Hokland, M., Goldfarb, R. H., Nagelkerke, J. F., Nannmark, U. and Kuppen, P. J. : NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends. Immunol. 24, 603 (2003).   DOI   ScienceOn
15 Le Maux Chansac, B., Moretta, A., Vergnon, I., Opolon, P., Lecluse, Y., Grunenwald, D., Kubin, M., Soria, J. C., Chouaib, S. and Mami-Chouaib, F. : NK cells infiltrating a MHC class Ideficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J. Immunol. 175, 5790 (2005).   DOI
16 Sun, Z., Chi, L., Zhang, H., Shao, Y., Lin, Y., Li, X. and Bai, C. Immune modulation and safety profile of adoptive immunotherapy using expanded autologus activeated lymphocutes against advanced cancer. Clin. Immunol. 138, 23 (2011).   DOI   ScienceOn
17 Salaginanni, M., Lekka, E., Moustaki, A., Lliopoulou, E. G., Baxevanis, C. N., Papamichail, M. and Perez, S. A. : Nk cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J. Immunol. 186, 3327 (2011).   DOI   ScienceOn
18 Gross, S. and Walden, P. : Immunosuppressive mechanisms in human tumors: Why we still cannot cure cancer. Immunol. Lett. 116, 7 (2008).   DOI   ScienceOn
19 Hallett, W. H. and Murphy, W. : Natural killer cells: biology and clinical use in cancer therapy. Cell. Mol. Immunol. 1, 12 (2004).
20 Herberman, R. B. : Cancer immunotherapy with natural killer cells. Semin Oncology 3, 27 (2002).
21 Klingemann, H. G. : Natural killer cell-based immunotherapeutic strategies. Cytotherapy 7, 16 (2005).   DOI
22 Bremers, A. J., Kuppen, P. J. and Parmiani, G. : Tumour immunotherapy: the adjuvant treatment of the 21st century. Eur. J. Surg. Oncol. 26, 418 (2000).   DOI   ScienceOn
23 Ljunggren, H. G. and Malmberg, K. J. : Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7, 329 (2007).   DOI   ScienceOn
24 Sentman, C. L., Barber, M. A., Barber, A. and Zhang, T. : NK cell receptors as tools in cancer immunotherapy. Adv. Cancer. Res. 95, 249 (2006).
25 Zamai, L., Ponti, C., Mirandola, P., Gobbi, G., Papa, S., Galeotti, L., Cocco, L. and Vitale, M. : NK cells and cancer. J. Immunol. 178, 4011 (2007).   DOI
26 Kalinski, P., Nakamura, Y., Watchmaker, P., Giermasz, A., Muthuswamy, R. and Mailliard, R. B. : Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines. Immunol. Res. 36, 137 (2006).   DOI
27 Sung, H., Kim, J. Y., Park, M. G., Kim, I., Lee, D. W., Han, S., Lee, C. and Song, S. : Anticancer effect of activated natural killer cells on human colorectal tumor. Yakhak Hoeji 54, 192 (2010).
28 deMagalhaes-Silverman, M., Donnenberg, A., Lembersky, B., Elder, E., Lister, J., Rybka, W., Whiteside, T. and Ball, E. : Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J. Immunother. 23, 154 (2000).   DOI   ScienceOn
29 Ahmedim, J., Bray, F., Melissa, M., Jacques, F., Ward, E. and Forman, D. : Global cancer statistics. CA Cancer. J. Ciln. 69 (2011).
30 Gaijar, A. and Lichtman, S. M. : Treatment of advanced lung cancer in erderly. Hosp. Pract. 39, 107 (2011).
31 Terunuma, H., Deng, X., Dewan, Z., Fujimoto, S. and Yamamoto, N. : Potential role of NK cells in the induction of immune responses: implications for NK cell-based immunotherapy for cancers and viral infections. Int. Rev. Immunol. 27, 93 (2008).   DOI   ScienceOn